Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Microbiome and EGFR-mutant non-small cell lung cancer: a complex interplay.

Expert review of clinical immunology - 1 Mar 2026

Eccher Serena, Sposito Marco, Scaglione Ilaria Mariangela, Pasqualin Luca, Rota Michele, Bonato Adele, Longo Lucia, Avancini Alice, Trestini Ilaria, Tregnago Daniela, Insolda Jessica, Milella Michele, Pilotto Sara, Belluomini Lorenzo

Abstract excerpt

INTRODUCTION: Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) exhibits unique biological and therapeutic characteristics. Although EGFR tyrosine kinase inhibitors (EGFR-TKIs) offer substantial clinical benefits, resistance development and treatment-related toxicities remain major challenges. Emerging evidence indicates that the host microbiome may significantly influence the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Lung Neoplasms

Share to Microbiota

Share to Molecular Targeted Therapy

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 41820290
DOI: 10.1080/1744666X.2026.2645844

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Microbiome and EGFR-mutant non-small cell lung cancer: a complex interplay.PMID 41820290Read ↗

The Complex Role of the Microbiome in Non-Small Cell Lung Cancer Development and ProgressionSemantic proximity Read ↗

Understanding Microbiome Effect on Immune Checkpoint Inhibition in Lung Cancer: Placing the Puzzle Pieces TogetherSemantic proximity Read ↗

Microbial biomarker development for detection and prognosis of early-stage non-small cell lung cancerSemantic proximity Read ↗

Gut Microbiota a Novel Source of Biomarkers for Immunotherapy in Non-small Cell Lung Cancer (NSCLC)Semantic proximity Read ↗

Gastrointestinal microbiota profile and clinical correlations in advanced EGFR-WT and EGFR-mutant non-small cell lung cancer.Semantic proximity Read ↗

The microbiome in the pathogenesis of lung cancerSemantic proximity Read ↗

Microbiome: A Supportive or a Leading Actor in Lung Cancer?Semantic proximity Read ↗

Gut microbiome and response to checkpoint inhibitors in non-small cell lung cancer—A reviewSemantic proximity Read ↗

Human Microbiome as Clinical Biomarkers for Respiratory Tract CancersSemantic proximity Read ↗

Intratumoral Resident Microbes Directly Participate in Resistance to EGFR-TKI Targeted Drug Therapy through Metabolism in NSCLCSemantic proximity Read ↗

Metagenomic and Metabolomic Correlates of Immunotherapy Response in Non-Small Cell Lung CancerSemantic proximity Read ↗

Unveiling the distinctive variations in multi-omics triggered by TP53 mutation in lung cancer subtypes: An insight from interaction among intratumoral microbiota, tumor microenvironment, and pathology.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.